An expression signature of 19 human endogenous retroviruses identifies immunogenic luminal breast cancers likely to respond to immunotherapy - Scorecard - MDSpire

An expression signature of 19 human endogenous retroviruses identifies immunogenic luminal breast cancers likely to respond to immunotherapy

  • By

  • Silvia Mihaela Ilie

  • Julie Lecuelle

  • François Ghiringhelli

  • Caroline Truntzer

  • Sylvain Ladoire

  • June 16, 2026

  • 0 min

Share

Clinical Scorecard: A 19 HERV Expression Profile Identifies Luminal Breast Cancer Subtypes with Potential Immunotherapy Responsiveness

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with HR+HER2− early breast cancer
Care Setting

Key Highlights

  • Identification of a 19 HERV expression signature linked to tumor immunogenicity

Guideline-Based Recommendations

Diagnosis

    Management

    • Assess the Breast HERV19 signature for immunotherapy responsiveness

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Patients with HR+HER2− early breast cancer

        Potential for immunotherapy based on HERV expression profile

        Clinical Best Practices

          Related Resources & Content

          Original Source(s)

          An expression signature of 19 human endogenous retroviruses identifies immunogenic luminal breast cancers likely to respond to immunotherapy

          • by Silvia Mihaela Ilie, Julie Lecuelle, François Ghiringhelli, Caroline Truntzer, Sylvain Ladoire

          • June 16, 2026

          Related Content

          Correction: Editorial: Epigenomics and metabolomics: pioneering new frontiers in breast cancer research and treatment

          The gastrin-releasing peptide receptor in oncology: a comprehensive review of recent advances in targeted radionuclide theranostics

          A case report of synchronous bilateral breast cancer with distinct histological subtypes and favorable long-term survival